315 related articles for article (PubMed ID: 30851646)
1. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
2. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
3. Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.
Belur Nagaraj A; Kovalenko O; Avelar R; Joseph P; Brown A; Surti A; Mantilla S; DiFeo A
Clin Cancer Res; 2018 Sep; 24(18):4588-4601. PubMed ID: 29653924
[No Abstract] [Full Text] [Related]
4. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
5. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
Giovinazzi S; Bellapu D; Morozov VM; Ishov AM
Cell Cycle; 2013 Aug; 12(16):2598-607. PubMed ID: 23907120
[TBL] [Abstract][Full Text] [Related]
6. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
7. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic relevance of the protein phosphatase 2A in cancer.
Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
[TBL] [Abstract][Full Text] [Related]
9. Nocodazole-Induced Expression and Phosphorylation of Anillin and Other Mitotic Proteins Are Decreased in DNA-Dependent Protein Kinase Catalytic Subunit-Deficient Cells and Rescued by Inhibition of the Anaphase-Promoting Complex/Cyclosome with proTAME but Not Apcin.
Douglas P; Ye R; Radhamani S; Cobban A; Jenkins NP; Bartlett E; Roveredo J; Kettenbach AN; Lees-Miller SP
Mol Cell Biol; 2020 Jun; 40(13):. PubMed ID: 32284347
[TBL] [Abstract][Full Text] [Related]
10. Mitotic slippage: an old tale with a new twist.
Sinha D; Duijf PHG; Khanna KK
Cell Cycle; 2019 Jan; 18(1):7-15. PubMed ID: 30601084
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality in
Noack S; Raab M; Matthess Y; Sanhaji M; Krämer A; Győrffy B; Kaderali L; El-Balat A; Becker S; Strebhardt K
Oncotarget; 2018 May; 9(40):25842-25859. PubMed ID: 29899826
[TBL] [Abstract][Full Text] [Related]
12. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
13. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis.
Eckerdt F; Strebhardt K
Cancer Res; 2006 Jul; 66(14):6895-8. PubMed ID: 16849530
[TBL] [Abstract][Full Text] [Related]
15. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
16. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
18. c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability.
Menssen A; Epanchintsev A; Lodygin D; Rezaei N; Jung P; Verdoodt B; Diebold J; Hermeking H
Cell Cycle; 2007 Feb; 6(3):339-52. PubMed ID: 17297307
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
[TBL] [Abstract][Full Text] [Related]
20. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
